Adare Pharma Solutions Expanding Oral Dose Capabilities In Europe

LAWRENCEVILLE, NJ, March 12, 2024 — Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced it is further investing in its Pessano facility in Milan, Italy, with the addition of a high-shear mixer granulator to complement existing fluid bed capabilities. This addition follows the recently announced expansion of blister packaging and warehousing capabilities at the site.

To facilitate diversification of oral dosage capabilities, the Pessano facility will add an IMA 600-L Roto Mix high-shear mixer with IMILL and Hydrowash, which can provide wet granulation using either aqueous or organic-based solutions. Located within a dedicated suite, the mixer features a ‘clean in place’ design to reduce the changeover times and consumption of water and energy associated with traditional machine clean-down routines. The new granulation suite will become operational in Q3 of 2024.

“Our Pessano facility has long provided our customers with superior oral technologies, including micro and mini tablets, plain and coated tablets, and capsules,” commented Tom Sellig, CEO of Adare Pharma Solutions. “Pessano’s powerful new mixer granulator, along with the site’s expanded packaging and warehousing offerings, allows us to provide even broader capabilities and further meet the needs of our customers.”

The 20,400 square meter Pessano facility provides R&D services to expedite formulation and process development, with a seamless integrated transition to manufacturing. It is capable of manufacturing a wide range of solid dosage forms at both clinical and commercial scales, including granules, capsules, and tablets. The facility also provides controlled substance and organic solvent capabilities.


About Adare Pharma Solutions
Adare Pharma Solutions is a global technology-driven contract development and manufacturing organization (CDMO) providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, customized release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare’s seven facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide. Learn more at www.adarepharmasolutions.com.